Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | ADAM17 | P78536 | 3/20 | 0.34 |
| ▸ | Q9HBH1 | 1/20 | 0.33 | |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | MMP1 | P03956 | 7/20 | 0.31 |
| ▸ | MMP3 | P08254 | 6/20 | 0.31 |
| ▸ | MMP9 | P14780 | 6/20 | 0.31 |
| ▸ | MMP2 | P08253 | 6/20 | 0.31 |
| ▸ | MMP8 | P22894 | 4/20 | 0.31 |
| ▸ | MMP13 | P45452 | 3/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
| ▸ | MMP7 | P09237 | 2/20 | 0.30 |
| ▸ | MMP14 | P50281 | 2/20 | 0.30 |
| ▸ | MMP20 | O60882 | 1/20 | 0.30 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.30 |
| ▸ | TNF | P01375 | 1/20 | 0.30 |
| ▸ | MMP10 | P09238 | 1/20 | 0.30 |
| ▸ | MMP12 | P39900 | 1/20 | 0.30 |
| ▸ | MMP15 | P51511 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6098 | 1.00 | HIF1A (0.34) | HIF1AADAM17PDFCA1CA2 | |
| Hydrochloric Acid SCHEMBL2286815 | 0.98 | HIF1A (0.33) | HIF1AADAM17PDFCA1CA2 | |
| SCHEMBL1213869 | 0.85 | CA2 (0.46) | CA1CA2CA7 | |
| SCHEMBL21012805 | 0.83 | HIF1A (0.31) | HIF1ACA1CA2 | |
| Hydrochloric Acid SCHEMBL30205399 | 0.82 | HIF1A (0.30) | HIF1A | |
| SCHEMBL13051146 | 0.82 | ADAM17 (0.48) | ADAM17MMP1MMP3MMP9MMP2 | |
| SCHEMBL4676064 | 0.79 | HIF1A (0.37) | HIF1AADAM17PDFCA1CA2 | |
| SCHEMBL3556829 | 0.79 | HIF1A (0.37) | HIF1AADAM17PDFCA1CA2 | |
| SCHEMBL10204084 | 0.79 | CNR2 (0.35) | CA1CA2MMP9CA7 | |
| SCHEMBL7765969 | 0.79 | CNR2 (0.35) | CA1CA2MMP9CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10806794-B2 | Protease inhibitors having enhanced features | NEKTAR THERAPEUTICS (US) | 2020-10-20 | — | — | US | disclosed |
| EP-2069303-B1 | ANTIVIRAL PROTEASE INHIBITORS | GILEAD SCIENCES INC (US) | 2016-03-30 | — | — | EP | disclosed |
| EP-2440249-A2 | COVALENT CONJUGATES COMPRISING A PROTEASE INHIBITOR, A WATER-SOLUBLE, NON-PEPTIDIC OLIGOMER AND A LIPOPHILIC MOIETY | Nektar Therapeutics (US) | 2012-04-18 | — | — | EP | disclosed |
| WO-2010144869-A2 | PROTEASE INHIBITORS | NEKTAR THERAPEUTICS (US) | 2010-12-16 | — | — | WO | disclosed |
| US-7723380-B2 | Tetrahydrofuro[2,3-b]furyl carbamates containing an (oxy)hydrazide group; these compounds target the HIV protease in both wild type and mutant strains of HIV. | GILEAD SCIENCES, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-7723380-B2 | Tetrahydrofuro[2,3-b]furyl carbamates containing an (oxy)hydrazide group; these compounds target the HIV protease in both wild type and mutant strains of HIV. | GILEAD SCIENCES, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| WO-2010033219-A2 | PROTEASE INHIBITORS HAVING ENHANCED FEATURES | NEKTAR THERAPEUTICS (US) | 2010-03-25 | — | — | WO | disclosed |
| US-20090306112-A1 | ANTIVIRAL PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090306112-A1 | ANTIVIRAL PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090105279-A1 | Antiviral protease inhibitors | GILEAD SCIENCES, INC. | 2009-04-23 | — | — | US | disclosed |
| US-20090105279-A1 | Antiviral protease inhibitors | GILEAD SCIENCES, INC. | 2009-04-23 | — | — | US | disclosed |
| WO-2008011117-A2 | ANTIVIRAL PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10806794-B2 | Protease inhibitors having enhanced features | SERPINB1, SPINT2, TMPRSS15 | HIF1A 2112/4885ADAM17 40/4885PDF 1820/4885 |
| US-20090105279-A1 | Antiviral protease inhibitors | ACE, TMPRSS15, MME | HIF1A 2138/4885ADAM17 46/4885PDF 2486/4885 |
| US-20090306112-A1 | ANTIVIRAL PROTEASE INHIBITORS | ACE, DNPEP, TMPRSS15 | HIF1A 2159/4885ADAM17 46/4885PDF 2628/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.